Pet Safety / Compounds / Atorvastatin

Is Atorvastatin safe for dogs and cats?

Moderate risk for pets

(Dogs-specific data is limited; this page draws from cat context.) Statins, including atorvastatin, are NOT used therapeutically in cats and feline accidental ingestion of human statin medications is a recognized veterinary concern; cats appear more sensitive to statin-induced myopathy and hepatotoxicity than dogs. Feline metabolism: cats have limited hepatic CYP3A4 activity and may metabolize statins differently than humans or dogs; reduced metabolic clearance leads to higher plasma concentrations per dose in cats. Toxic dose threshold: ASPCA APCC data for statin toxicity in cats indicate clinical signs at relatively lower doses than in dogs; signs begin at approximately 2–4 mg/kg in cats. Signs: GI signs (vomiting, anorexia) are most common; muscle weakness, elevated CK, and liver enzyme elevations with higher exposures; rhabdomyolysis in severe cases. Treatment: induce vomiting if recent ingestion; activated charcoal; supportive care including IV fluids to protect kidneys from myoglobin; monitoring CK and liver enzymes. Rosuvastatin exception: rosuvastatin is not metabolized by CYP3A4 and has a different safety profile; nonetheless, all statins should be considered potentially toxic to cats pending further data. Lipitor tablets: the commonly prescribed 10 mg, 20 mg, 40 mg, and 80 mg tablets are frequently found in households with cats; tablet accessibility (counter-surfing, floor drops) makes accidental ingestion common.

What is atorvastatin?

The IUPAC name is (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid.

Also known as: (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid, Cardyl, atorvastatina, atorvastatine.

IUPAC name: (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
CAS number: 134523-00-5
Molecular formula: C33H35FN2O5
Molecular weight: 558.6 g/mol
SMILES: CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
PubChem CID: 60823

Risk for dogs

Moderate risk

Statins, including atorvastatin, are NOT used therapeutically in cats and feline accidental ingestion of human statin medications is a recognized veterinary concern; cats appear more sensitive to statin-induced myopathy and hepatotoxicity than dogs. Feline metabolism: cats have limited hepatic CYP3A4 activity and may metabolize statins differently than humans or dogs; reduced metabolic clearance leads to higher plasma concentrations per dose in cats. Toxic dose threshold: ASPCA APCC data for statin toxicity in cats indicate clinical signs at relatively lower doses than in dogs; signs begin at approximately 2–4 mg/kg in cats. Signs: GI signs (vomiting, anorexia) are most common; muscle weakness, elevated CK, and liver enzyme elevations with higher exposures; rhabdomyolysis in severe cases. Treatment: induce vomiting if recent ingestion; activated charcoal; supportive care including IV fluids to protect kidneys from myoglobin; monitoring CK and liver enzymes. Rosuvastatin exception: rosuvastatin is not metabolized by CYP3A4 and has a different safety profile; nonetheless, all statins should be considered potentially toxic to cats pending further data. Lipitor tablets: the commonly prescribed 10 mg, 20 mg, 40 mg, and 80 mg tablets are frequently found in households with cats; tablet accessibility (counter-surfing, floor drops) makes accidental ingestion common.

Risk for cats

Moderate risk

Regulatory consensus

1 regulatory bodyhas classified Atorvastatin.

Agency	Year	Classification	Notes
FDA	—	Approved for primary and secondary prevention of cardiovascular events, treatment of hypercholesterolemia and mixed dyslipidemia, and familial hypercholesterolemia

Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.

Where pets encounter atorvastatin

Industrial Facilities — Manufacturing plants, Chemical storage areas, Waste treatment sites
Occupational Environments — Factories, Warehouses, Transportation vehicles

Safer alternatives

Lower-risk approaches that achieve a similar outcome to Atorvastatin:

Alternative drug class; Non-pharmacological therapy; Lowest effective dose
Trade-offs: Direct chemical substitution requires verification that the replacement does not introduce new hazards (regrettable substitution). Conduct full hazard assessment of proposed alternative before adoption.

Relative cost: 1.2-2×

Frequently asked questions

What products contain atorvastatin?

Atorvastatin appears in: Manufacturing plants (Industrial facilities); Chemical storage areas (Industrial facilities); Factories (Occupational environments); Warehouses (Occupational environments).

See Atorvastatin in the pets app

Look up products containing atorvastatin, compare to alternatives, and explore the full data record.

Open in pets View raw API data

Sources (2)

FDA Prescribing Information: Atorvastatin (Lipitor) — HMG-CoA reductase inhibitor; myopathy/rhabdomyolysis; CYP3A4 substrate; clarithromycin dose cap; hepatotoxicity; diabetes risk; pediatric HeFH ≥10yr; pregnancy Category X; statin intolerance (2023) (2023) — regulatory
ASPCA Animal Poison Control Center: Cardiac Drug Toxicosis in Pets — statin myopathy in cats; beta-blocker bradycardia dogs; CCB toxicity (amlodipine/diltiazem); ACE inhibitor renal effects; warfarin anticoagulant; furosemide; toxic dose thresholds (2023) (2023) — veterinary

Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →